Average Co-Inventor Count = 2.77
ph-index = 41
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Idera Pharmaceuticals, Inc. (79 from 79 patents)
2. Hybridon, Inc. (53 from 98 patents)
3. Worcester Foundation for Experimental Biology (10 from 18 patents)
4. University of Massachusetts (3 from 1,551 patents)
5. Worcester Foundation for Biomedical Research (3 from 6 patents)
6. Other (2 from 832,680 patents)
7. The Norwegian Radium Hospital Research Foundation (2 from 4 patents)
8. The General Hospital Corporation (1 from 2,882 patents)
9. Mount Sinai School of Medicine (1 from 242 patents)
10. Idera Pharmaceutials, Inc. (1 from 1 patent)
152 patents:
1. 11224611 - Immune modulation with TLR9 agonists for cancer treatment
2. 10835550 - Immune modulation with TLR9 agonists for cancer treatment
3. 10772907 - Immune modulation with TLR9 agonists for cancer treatment
4. 10463686 - Immune modulation with TLR9 agonists for cancer treatment
5. 10066230 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
6. 10041076 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
7. 9828601 - Compositions for inhibiting checkpoint gene expression and uses thereof
8. 9688993 - Toll-like receptor 9 antagonist and methods of use thereof
9. 9540651 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
10. 9453228 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
11. 9260719 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
12. 9243050 - Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
13. 9206430 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
14. 9096858 - Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
15. 8987221 - Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9